PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDeborah B. Doroshow, Fred R. Hirsch, Sheena Bhalla et al.|Nature Reviews Clinical Oncology|2021Cited by 1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaLevi A. Garraway, William R. Sellers, Hans R. Widlund et al.|Nature|2005Cited by 1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J. Creighton, Jenny C. Chang, Xiaoxian Li et al.|Proceedings of the National Academy of Sciences|2009Cited by 1.4k
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerJoseph McLaughlin, David L. Rimm|JAMA Oncology|2015Cited by 834
Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, David L. Rimm, Kurt A. Schalper et al.|Laboratory Investigation|2013Cited by 753